Log in to your Inderes Free account to see all free content on this page.
Genmab
1,843.00 DKK
+2.65 %
Less than 1K followers
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Genmab
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 5,366.0 | 10,111.0 | 8,482.0 | 14,595.0 | 16,474.0 | 21,526.0 | 23,653.5 |
| growth-% | 88.4 % | -16.1 % | 72.1 % | 12.9 % | 30.7 % | 9.9 % | |
| EBITDA | 2,638.0 | 6,313.0 | 3,018.0 | 6,357.0 | 5,321.0 | 7,116.0 | 7,426.7 |
| EBIT | 2,638.0 | 6,313.0 | 3,018.0 | 6,357.0 | 5,321.0 | 6,703.0 | 6,771.8 |
| Profit before taxes | 2,859.0 | 5,904.0 | 3,983.0 | 7,035.0 | 5,637.0 | 9,164.0 | 7,655.6 |
| Net income | 2,166.0 | 4,758.0 | 3,008.0 | 5,522.0 | 4,352.0 | 7,844.0 | 6,123.2 |
| EPS | 33.34 | 73.24 | 46.30 | 84.45 | 66.64 | 122.21 | 98.56 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 49.2 % | 62.4 % | 35.6 % | 43.6 % | 32.3 % | 33.1 % | 31.4 % |
| EBIT-% | 49.2 % | 62.4 % | 35.6 % | 43.6 % | 32.3 % | 31.1 % | 28.6 % |
| ROE | 15.4 % | 24.9 % | 13.6 % | 20.1 % | 13.8 % | 21.4 % | 16.5 % |
| ROI | 14.3 % | 22.5 % | 12.2 % | 18.2 % | 12.3 % | 17.1 % | 7.5 % |
Login required
This content is only available for logged in users